Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2001

View Archived Issues

Licensing opportunity from NIH: ocular delivery devices and methods

Protein with potential as malaria vaccine available for licensing from NIH

Alliance's LiquiVent shows potential for enhancing Ad-mediated gene expression

Xenogen expands licensing agreement with Lilly

Another major launch for Reductil

Novel class of chimeric antimalarial compounds under development by new company

Phase II trial begins to evaluate Angiozyme for the treatment of colorectal cancer

Georgetown grants Samaritan exclusive worldwide license to Alzheimer's patent

Antisense oligonucleotide reverses cognitive deficits in SAMP8 mice after i.v. administration

MabThera monoclonal antibody approved in Japan

Subtype-selective metabotropic glutamate receptor antagonists particularly useful for pain, migraine

Aventis prepares new series of compounds for obesity and diabetes

Cytotoxic topoisomerase inhibitors identified by Rutgers scientists

VEGF inhibitors in the AstraZeneca pipeline

Merck patents pyrrole-based PDE7/TNF-alpha production inhibitors

Novel serotonergic compounds from GSK particularly useful for depression

InterMune highlights recent corporate development activities

Grupo Vita uses Spain as reference member state for approval of enalapril/nitrendipine

Roche presents new antibacterial compounds that inhibit bacterial DHFR

Sepracor evaluates sustained-release formulation of (S)-oxybutynin in phase III

NeuroSearch to carry out phase III development of NS-2330 independently

Synthetic peptides inhibit interaction between prion protein isoforms

Phase II Naltrel data for alcohol and heroin addiction presented at Drug Dependence meeting

Irofulven/gemcitabine combination under evaluation in advanced cancers

Patient enrollment completed in phase III trial of CeaVac

Bayer and CuraGen make great strides in obesity/diabetes drug development alliance

EULAR 2001: long-term efficacy and safety of etoricoxib in RA and OA

Leflunomide metabolite blocks cytokine-induced CD69 upregulation in human PBLs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...